Cross talk between EBV and telomerase: The role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus

Cell Death and Disease

Volumn 6, Issue 5, 2015, Pages

  Giunco, S ^a   Celeghin, A ^a   Gianesin, K ^a   Dolcetti, R ^b   Indraccolo, S ^c   De Rossi, A ^a,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMEDIATE EARLY PROTEIN BZLF1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NOTCH2 RECEPTOR; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; BATF PROTEIN, HUMAN; BZLF1 PROTEIN, HERPESVIRUS 4, HUMAN; NOTCH2 PROTEIN, HUMAN; TERT PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ARTICLE; CELL DEATH; CONTROLLED STUDY; ECTOPIC EXPRESSION; ENZYME ACTIVATION; EPSTEIN BARR VIRUS; GENE OVEREXPRESSION; GENE SILENCING; GENE SWITCHING; HUMAN; HUMAN CELL; IN VITRO STUDY; LATENT VIRUS INFECTION; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; UPREGULATION; VIRUS INHIBITION; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; BIOSYNTHESIS; CELL LINE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; VIROLOGY; VIRUS LATENCY;

B-LYMPHOCYTES; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL LINE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; NF-KAPPA B; PROMOTER REGIONS, GENETIC; RECEPTOR, NOTCH2; RNA, MESSENGER; SIGNAL TRANSDUCTION; TELOMERASE; TRANS-ACTIVATORS; VIRUS LATENCY;

EID: 84943378004     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.145     Document Type: Article

References (69)

1. Kieff ED, Rickinson AB. Epstein-Barr virus and its replication. In: Knipe DM, Howley PM (eds). Field's Virology, 5th edn. Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2007, pp 2603-2654.
2. Sugimoto M, Tahara H, Ide T, Furuichi Y. Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. Cancer Res 2004; 64: 3361-3364.
3. Terrin L, Dolcetti R, Corradini I, Indraccolo S, Col JD, Bertorelle R et al. hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis. Int J Cancer 2007; 121: 576-587.
4. Jeon JP, Nam HY, Shim SM, Han BG. Sustained viral activity of Epstein-Barr virus contributes to cellular immortalization of lymphoblastoid cell lines. Mol Cells 2009; 27: 143-148.
5. Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med 2006; 12: 1133-1138.
6. Verdun RE, Karlseder J. Replication and protection of telomeres. Nature 2007; 447: 924-931.
7. Martínez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer 2011; 11: 161-176.
8. Li Y, Tergaonkar V. Noncanonical functions of telomerase: implications in telomerasetargeted cancer therapies. Cancer Res 2014; 74: 1639-1644.
9. Giunco S, Dolcetti R, Keppel S, Celeghin A, Indraccolo S, Dal Col J et al. hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies. Clin Cancer Res 2013; 19: 2036-2047.
10. Dolcetti R, Giunco S, Dal Col J, Celeghin A, Mastorci K, De Rossi A. Epstein-Barr virus and telomerase: from cell immortalization to therapy. Infect Agent Cancer 2014; 9: 8.
11. Dorsey MJ, Tae HJ, Sollenberger KG, Mascarenhas NT, Johansen LM, Taparowsky EJ. B-ATF: a novel human bZIP protein that associates with members of the AP-1 transcription factor complex. Oncogene 1995; 11: 2255-2265.
12. Echlin D, Tae HJ, Mitin N, Taparowsky EJ. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos. Oncogene 2000; 19: 1752-1763.
13. Johansen LM, Deppmann CD, Erickson KD, Coffin WF 3rd, Thornton TM, Humphrey SE et al. EBNA2 and activated Notch induce expression of BATF. J Virol 2003; 77: 6029-6040.
14. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999; 284: 770-776.
15. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood 2006; 107: 2223-2233.
16. Miele L. Notch signaling. Clin Cancer Res 2006; 12: 1074-1079.
17. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009; 137: 216-233.
18. Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell 2009; 16: 633-647.
19. Saito T, Chiba S, Ichikawa M, Kunisato A, Asai T, Shimizu K et al. Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity 2003; 18: 675-685.
20. Hubmann R, Düchler M, Schnabl S, Hilgarth M, Demirtas D, Mitteregger D et al. NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells. Br J Haematol 2010; 148: 868-878.
21. Hubmann R, Hilgarth M, Schnabl S, Ponath E, Reiter M, Demirtas D et al. Gliotoxin is a potent NOTCH2 transactivation inhibitor and efficiently induces apoptosis in chronic lymphocytic leukaemia (CLL) cells. Br J Haematol 2013; 160: 618-629.
22. Duechler M, Shehata M, Schwarzmeier JD, Hoelbl A, Hilgarth M, Hubmann R. Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2. Leukemia 2005; 19: 260-267.
23. Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni M, Fettucciari K et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 2009; 113: 856-865.
24. Rosati E, Sabatini R, De Falco F, Del Papa B, Falzetti F, Di Ianni M et al. γ-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation. Int J Cancer 2013; 132: 1940-1953.
25. Trøen G, Wlodarska I, Warsame A, Hernández Llodrà S, De Wolf-Peeters C, Delabie J. NOTCH2 mutations in marginal zone lymphoma. Haematologica 2008; 93: 1107-1109.
26. Lee SY, Kumano K, Nakazaki K, Sanada M, Matsumoto A, Yamamoto G et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci 2009; 100: 920-926.
27. Zhang X, Shi Y, Weng Y, Lai Q, Luo T, Zhao J et al. The truncate mutation of Notch2 enhances cell proliferation through activating the NF-κB signal pathway in the diffuse large B-cell lymphomas. PLoS One 2014; 9: e108747.
28. Jundt F, Anagnostopoulos I, Förster R, Mathas S, Stein H, Dörken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002; 99: 3398-3403.
29. Schwarzer R, Jundt F. Notch and NF-κB signaling pathways in the biology of classical Hodgkin lymphoma. Curr Mol Med 2011; 11: 236-245.
30. Schwarzer R, Dörken B, Jundt F. Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells. Leukemia 2012; 26: 806-813.
31. Peng M, Lundgren E. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 1992; 7: 1775-1782.
32. Wang D, Liebowitz D, Wang F, Gregory C, Rickinson A, Larson R et al. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 1988; 62: 4173-4184.
33. Ungerbäck J, Elander N, Grünberg J, Sigvardsson M, Söderkvist P. The Notch-2 gene is regulated by Wnt signaling in cultured colorectal cancer cells. PLoS One 2011; 6: e17957.
34. Bachand F, Boisvert FM, Côté J, Richard S, Autexier C. The product of the survival of motor neuron (SMN) gene is a human telomerase-associated protein. Mol Biol Cell 2002; 13: 3192-3202.
35. Park JI, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 2009; 460: 66-72.
36. Ghosh A, Saginc G, Leow SC, Khattar E, Shin EM, Yan TD et al. Telomerase directly regulates NF-κB-dependent transcription. Nat Cell Biol 2012; 14: 1270-1281.
37. Ding D, Xi P, Zhou J, Wang M, Cong YS. Human telomerase reverse transcriptase regulates MMP expression independently of telomerase activity via NF-κB-dependent transcription. FASEB J 2013; 27: 4375-4383.
38. Wang H, Tian Y, Wang J, Phillips KL, Binch AL, Dunn S et al. Inflammatory cytokines induce NOTCH signaling in nucleus pulposus cells: implications in intervertebral disc degeneration. J Biol Chem 2013; 288: 16761-16774.
39. Terrin L, Dal Col J, Rampazzo E, Zancai P, Pedrotti M, Ammirabile G et al. Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes. J Virol 2008; 82: 10175-10187.
40. Hajdu M, Kopper L, Sebestyén A. Notch-regulation upon Dll4-stimulation of TGFb-induced apoptosis and gene expression in human B-cell non-Hodgkin lymphomas. Scand J Immunol 2010; 71: 29-37.
41. Moore SM, Cannon JS, Tanhehco YC, Hamzeh FM, Ambinder RF. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother 2001; 45: 2082-2091.
42. Feng WH, Cohen JI, Fischer S, Li L, Sneller M, Goldbach-Mansky R et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst 2004; 96: 1691-1702.
43. Fu DX, Tanhehco Y, Chen J, Foss CA, Fox JJ, Chong JM et al. Bortezomib-induced enzymetargeted radiation therapy in herpesvirus-associated tumors. Nat Med 2008; 14: 1118-1122.
44. Meng Q, Hagemeier SR, Fingeroth JD, Gershburg E, Pagano JS, Kenney SC. The Epstein- Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production. J Virol 2010; 84: 4534-4542.
45. Murata T. Regulation of Epstein-Barr virus reactivation from latency. Microbiol Immunol 2014; 58: 307-317.
46. Kenney SC, Mertz JE. Regulation of the latent-lytic switch in Epstein-Barr virus. Semin Cancer Biol 2014; 26: 60-68.
47. Iempridee T, Reusch JA, Riching A, Johannsen EC, Dovat S, Kenney SC et al. Epstein-Barr virus utilizes Ikaros in regulating its latent-lytic switch in B cells. J Virol 2014; 88: 4811-4827.
48. Miller G, El-Guindy A, Countryman J, Ye J, Gradoville L. Lytic cycle switches of oncogenic human gammaherpesviruses. Adv Cancer Res 2007; 97: 81-109.
49. Bhaduri-McIntosh S, Miller G. Cells lytically infected with Epstein-Barr virus are detected and separable by immunoglobulins from EBV-seropositive individuals. J Virol Methods 2006; 137: 103-114.
50. Daigle D, Megyola C, El-Guindy A, Gradoville L, Tuck D, Miller G et al. Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors. J Virol 2010; 84: 993-1004.
51. Zimber-Strobl U, Strobl LJ. EBNA2 and Notch signalling in Epstein-Barr virus mediated immortalization of B lymphocytes. Semin Cancer Biol 2001; 11: 423-434.
52. Hayward SD. Viral interactions with the Notch pathway. Semin Cancer Biol 2004; 14: 387-396.
53. Anderson LJ, Longnecker R. Epstein-Barr virus latent membrane protein 2A exploits Notch1 to alter B-cell identity in vivo. Blood 2009; 113: 108-116.
54. Pal AD, Basak NP, Banerjee AS, Banerjee S. Epstein-Barr virus latent membrane protein- 2 A alters mitochondrial dynamics promoting cellular migration mediated by Notch signaling pathway. Carcinogenesis 2014; 35: 1592-1601.
55. Hubmann R, Schwarzmeier JD, Shehata M, Hilgarth M, Duechler M, Dettke M et al. Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. Blood 2002; 99: 3742-3747.
56. Rowe M, Raithatha S, Shannon-Lowe C. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions. J Virol 2014; 88: 12065-12076.
57. Tang W, Harmon P, Gulley ML, Mwansambo C, Kazembe PN, Martinson F et al. Viral response to chemotherapy in endemic Burkitt lymphoma. Clin Cancer Res 2010; 16: 2055-2064.
58. Feng WH, Kenney SC. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 2006; 66: 8762-8769.
59. Shirley CM, Chen J, Shamay M, Li H, Zahnow CA, Hayward SD et al. Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma. Blood 2011; 117: 6297-6303.
60. Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad F et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007; 109: 2571-2578.
61. Wildeman MA, Novalic Z, Verkuijlen SA, Juwana H, Huitema AD, Tan IB et al. Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors. Clin Cancer Res 2012; 18: 5061-5070.
62. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999; 21: 220-224.
63. Imbert-Marcille BM, Coste-Burel M, Robillard N, Foucaud-Gamen J, Billaudel S, Drouet E. Sequential use of paraformaldehyde and methanol as optimal conditions for the direct quantification of ZEBRA and rta antigens by flow cytometry. Clin Diagn Lab Immunol 2000; 7: 206-211.
64. Terrin L, Rampazzo E, Pucciarelli S, Agostini M, Bertorelle R, Esposito G et al. Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res 2008; 14: 7444-7451.
65. Ometto L, Menin C, Masiero S, Bonaldi L, Del Mistro A, Cattelan AM et al. Molecular profile of Epstein-Barr virus in human immunodeficiency virus type 1-related lymphadenopathies and lymphomas. Blood 1997; 90: 313-322.
66. Trentin L, Ballon G, Ometto L, Perin A, Basso U, Chieco-Bianchi L et al. Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. Br J Haematol 1999; 106: 662-668.
67. Ballon G, Ometto L, Righetti E, Cattelan AM, Masiero S, Zanchetta M et al. Human immunodeficiency virus type 1 modulates telomerase activity in peripheral blood lymphocytes. J Infect Dis 2001; 183: 417-424.
68. Colombrino E, Rossi E, Ballon G, Terrin L, Indraccolo S, Chieco-Bianchi L et al. Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein-Barr virus-immortalized B cells. Exp Cell Res 2004; 295: 539-548.
69. Righetti E, Ballon G, Ometto L, Cattelan AM, Menin C, Zanchetta M et al. Dynamics of Epstein-Barr virus in HIV-1-infected subjects on highly active antiretroviral therapy. AIDS 2002; 16: 63-73.